Literature DB >> 24352316

Outflanking HCV.

Zhigang Tian1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24352316     DOI： 10.1038/ni.2783

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  13 in total

Review 1.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 2.  Immunology of hepatitis B virus and hepatitis C virus infection.

Authors:  Barbara Rehermann; Michelina Nascimbeni
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

3.  Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Authors:  Robert E Lanford; Elisabeth S Hildebrandt-Eriksen; Andreas Petri; Robert Persson; Morten Lindow; Martin E Munk; Sakari Kauppinen; Henrik Ørum
Journal:  Science       Date:  2009-12-03       Impact factor: 47.728

4.  Treatment of HCV infection by targeting microRNA.

Authors:  Harry L A Janssen; Hendrik W Reesink; Eric J Lawitz; Stefan Zeuzem; Maribel Rodriguez-Torres; Keyur Patel; Adriaan J van der Meer; Amy K Patick; Alice Chen; Yi Zhou; Robert Persson; Barney D King; Sakari Kauppinen; Arthur A Levin; Michael R Hodges
Journal:  N Engl J Med       Date:  2013-03-27       Impact factor: 91.245

5.  Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions.

Authors:  Kayla A Holder; Staci N Stapleton; Maureen E Gallant; Rodney S Russell; Michael D Grant
Journal:  J Immunol       Date:  2013-08-19       Impact factor: 5.422

6.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

7.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

10.  The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs.

Authors:  Adelle P McFarland; Stacy M Horner; Abigail Jarret; Rochelle C Joslyn; Eckart Bindewald; Bruce A Shapiro; Don A Delker; Curt H Hagedorn; Mary Carrington; Michael Gale; Ram Savan
Journal:  Nat Immunol       Date:  2013-11-17       Impact factor: 25.606
View more
  3 in total

1.  Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library.

Authors:  Dik-Lung Ma; Daniel Shiu-Hin Chan; Guo Wei; Hai-Jing Zhong; Hui Yang; Lai To Leung; Elizabeth A Gullen; Pauline Chiu; Yung-Chi Cheng; Chung-Hang Leung
Journal:  Chem Commun (Camb)       Date:  2014-11-21       Impact factor: 6.222

2.  HCV core protein binds to gC1qR to induce A20 expression and inhibit cytokine production through MAPKs and NF-κB signaling pathways.

Authors:  Xiaotian Song; Zhiyan Yao; Jianling Yang; Zhengzheng Zhang; Yuqing Deng; Miao Li; Cuiqing Ma; Lijuan Yang; Xue Gao; Wenjian Li; Jianguo Liu; Lin Wei
Journal:  Oncotarget       Date:  2016-06-07

Review 3.  MicroRNA-Related Polymorphisms in Infectious Diseases-Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications.

Authors:  Joel Henrique Ellwanger; Francis Maria Báo Zambra; Rafael Lima Guimarães; José Artur Bogo Chies
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.